Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234-Reference-Cited by-同舟云学术

Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234

Published:2018-04-07 Issue:9 Volume:61 Page:4067-4086
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Papp-Wallace Krisztina M.¹,Nguyen Nhu Q.,Jacobs Michael R.²,Bethel Christopher R.¹,Barnes Melissa D.¹,Kumar Vijay,Bajaksouzian Saralee²,Rudin Susan D.¹,Rather Philip N.³⁴,Bhavsar Satish⁵,Ravikumar Tadiparthi⁵,Deshpande Prasad K.⁵,Patil Vijay⁵,Yeole Ravindra⁵,Bhagwat Sachin S.⁵,Patel Mahesh V.⁵,van den Akker Focco,Bonomo Robert A.¹^ORCID

Affiliation:

1. Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, 10701 East Boulevard, Cleveland, Ohio 44106, United States

2. Department of Pathology, University Hospitals, Cleveland Medical Center, Cleveland, Ohio 44106, United States

3. Department of Microbiology and Immunology, Emory University School of Medicine Atlanta, Georgia 30322, United States

4. Research Service, Atlanta VA Medical Center, Decatur, Georgia 30033, United States

5. Wockhardt Research Centre, Aurangabad, India

Funder

U.S. Department of Veterans Affairs

National Institute of Allergy and Infectious Diseases

Biomedical Laboratory Research and Development, VA Office of Research and Development

Wockhardt Research Centre

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b00091

Reference50 articles.

1. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

2. New β-Lactamase Inhibitors in the Clinic

3. Inactivation of CMY-2 β-lactamase by tazobactam: initial mass spectroscopic characterization

4. Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases

5. Avibactam is a covalent, reversible, non- -lactam -lactamase inhibitor

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Approachable Synthetic Methodologies for Second-Generation β-Lactamase Inhibitors: A Review;Pharmaceuticals;2024-08-23

2. Crystal structure of the class A extended-spectrum β-lactamase CTX-M-96 in complex with relebactam at 1.03 Angstrom resolution;Antimicrobial Agents and Chemotherapy;2024-08-07

3. Synthesis and evaluation of novel biaryl oxazolidinones effective against gram-positive bacterial infections;Medicinal Chemistry Research;2024-07-24

4. New Agents Are Coming, and So Is the Resistance;Antibiotics;2024-07-13

5. Evolving resistance landscape in gram‐negative pathogens: An update on β‐lactam and β‐lactam‐inhibitor treatment combinations for carbapenem‐resistant organisms;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07